Oncology Medical News

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Determination of the specific activity of CDK1 and CDK2 as a novel prognostic indicator for early breast cancer
Annals of Oncology, 01/03/08

Kim SJ et al. - In a study to investigate the prognostic significance of CDK1SA and CDK2SA in human breast cancer, it was shown that CDK1SA and CDK2SA may be useful in the prediction of outcomes in breast cancer patients and has potential for use as a routine laboratory test

Methods

CDK1SA and CDK2SA were determined in 284 breast cancer patients and their prognostic significance was investigated

Results

Tumors with high CDK1SA and CDK2SA showed significantly poorer 5-year relapse-free survival than those with low CDK1SA and CDK2SA, respectively
Combined analysis of CDK1SA and CDK2SA enabled the classification of breast tumors into high-risk and low-risk groups, where tumors in the high-risk group were strongly associated with unfavorable prognosis
The risk is a significant prognostic indicator for relapse, especially in node-negative patients

<< Previous
Taxane-based combinations as adjuvant chemotherapy of early...

Next >>
Phase II clinical trial of bevacizumab and low-dose metronomic...